Royalty Pharma RPRX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Royalty Pharma’s reported figures.
The official record: Royalty Pharma’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Royalty Pharma's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Royalty Pharma's enterprise value?
- Royalty Pharma (RPRX) reported enterprise value of $28.94B in Q1 2026.
- How has Royalty Pharma's enterprise value changed year-over-year?
- Royalty Pharma's enterprise value increased by 44.6% year-over-year, from $20.02B to $28.94B.
- What is the long-term trend for Royalty Pharma's enterprise value?
- Over 4 years (2021 to 2025), Royalty Pharma's enterprise value has grown at a 0.3% compound annual growth rate (CAGR), from $89.62B to $90.78B.
- What does enterprise value mean?
- What it would cost to buy the entire business, debt included and cash netted out.
- How do you interpret enterprise value?
- The capital-structure-neutral valuation base — used in EV/EBITDA and EV/Sales to compare companies with different leverage on a like-for-like footing.
- How does enterprise value compare across companies?
- Comparable across non-financial companies via the EV multiples it feeds; not used for banks and insurers.